1271-PUB: Real-World Effectiveness of Newly Initiated Once-Weekly Semaglutide (sema OW) by Prescriber Specialty

Abstract

Background: Both primary care physicians (PCPs) and endocrinologists (Endos) commonly prescribe T2D medications. This study presents real-world effectiveness of sema OW by prescriber specialty in a cohort of US commercially insured/Medicare Advantage T2D patients newly initiating a GLP-1 agonist. Methods: Claims and lab result data were used to identify T2D patients who initiated sema OW between 12/1/17 - 6/30/20 (index as first claim). Selected patients had ≥1 A1c result within ≤3 months pre and ≥3 months post-index. Patients with no claim for any GLP-1 agonist in the 12 months pre-index and persistent on sema OW (those with a sema OW prescription with days supply dispensed overlapping/in proximity of date of post-index A1c) were assessed for A1c changes stratified by prescriber specialty (PCPs/Endos) and by pre-index A1c >9%. Results: A1c was significantly reduced vs. pre-index in 1,284 patients prescribed sema OW by a PCP or Endo (both -1.3%; p 9% (both -2.8%; p Conclusion: Similar pre/post reductions in A1c were observed when initiating sema OW in T2D GLP-1 agonist naive patients being treated by PCPs and Endos. Disclosure N. Shivappa: Other Relationship; Self; Novo Nordisk. J. Noone: Employee; Self; Novo Nordisk Inc. C. Swift: Employee; Self; Novo Nordisk Inc. S. Du: None. H. Tan: Other Relationship; Self; HealthCore. Y. M. Paprocki: Employee; Self; Novo Nordisk, Stock/Shareholder; Self; Novo Nordisk. V. Willey: Employee; Self; HealthCore.